CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 32 enrolled
Drug / intervention
Bort, Dex, and Dox with ALCARdrug
Likely dose
Bort, Dex, and Dox with ALCAR 1.3 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00581919
NCT00581919Phase 2Completed
CompareCT.gov

Phase II Trial of Bortezomib, Low Dose Dexamethasone, and Doxorubicin With Acetyl-L-Carnitine for Neuroprotection in Patients With Previously Treated Multiple Myeloma

University of Wisconsin, Madison·interventional·Posted Dec 28, 2007·Updated Dec 13, 2019

In Brief

A Phase 2 clinical trial evaluating Bort, Dex, and Dox with ALCAR for Multiple Myeloma. Completed, enrolled 32 participants across 5 sites.

Detailed Summary

Patients will receive Bortezomib, Dexamethasone, and Doxorubicin in 21 day cycles a total of 4 to 8 times (based on response to the treatment). Patients will also receive acetyl-L-carnitine (ALCAR) daily.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
CollaboratorsMillennium Pharmaceuticals, Inc.

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 28, 2007
Enrollment StartFeb 1, 2004
Primary CompletionDec 1, 2010
Study CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 18.5 years ago

Interventions

Bort, Dex, and Dox with ALCARdrug

Bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 Dexamethasone 20 mg PO days 1, 4, 8, and 11 Doxorubicin 15 mg/m2 IV days 1 and 8 Acetyl-L-Carnitine (ALCAR) 1.5 g PO BID days 1-21 Maximum of 8 cycles. Each cycle is 21 days long